欢迎访问《现代生物医学进展》编辑部！

首页

期刊简介

编委会

编辑名单

投稿指南

学术会议

核心期刊证书

联系我们

English

文章摘要

陈华林杨东红王永存赖振南杨志雄.培美曲塞+ 顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌的近期疗效及安全性观察[J].,2015,15(13):2487-2490

培美曲塞+ 顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌的近期疗效及安全性观察

Clinicals Study of Short-termEfficacy and Safety of Pemetrexed CombinedWith Cisplatin Induction Concurrent Chemoradiotherapy in LocallyAdvanced Non-small-cell Lung Cancer

DOI：

中文关键词: 培美曲塞顺铂化疗同步放化疗局部晚期非小细胞肺癌近期疗效不良反应

英文关键词: Pemetrexed Cisplatin Chemotherapy Concurrent chernoradiotherapy Locally advanced non-small-cell lung cancer Short-termefficacyt Adverse reactions

基金项目:

作者	单位
陈华林杨东红王永存赖振南杨志雄	广东医学院附属医院肿瘤中心

摘要点击次数: 803

全文下载次数: 0

中文摘要:

目的：探究培美曲塞+顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌的近期疗效及安全性。方法：收集我院肿瘤科2009 年7 月到2011 年7 月住院治疗的局部晚期非鳞癌非小细胞癌患者54 例，按照随机数字表法分为研究组和对照组，每组27 例，研究组给予培美曲塞+顺铂方案诱导化疗联合同期放化疗，对照组仅给予培美曲塞+ 顺铂方案化疗联合同期放疗，治疗2 个周期,随访2年，对比两组患者的近期疗效及安全性。结果：研究组的近期有效率和控制率分别为55.56%、77.78%，高于对照组的50.33%和59.26%，有效率和控制率差异具有统计学意义（P<0.05）。随访2 年，研究组的中位生存期为12.77 个月，1 年生存率为48.15%，高于对照组中位生存期11.28 个月，1 年生存率40.74%，但差异无统计学意义（P>0.05），研究组2 年生存率为 43.46%，高于对照组的25.38%，差异具有统计学意义（P<0.05）；研究组白细胞减少以及脱发发生率分别为37.0%、25.9%，低于对照组的81.5%和55.5%，差异具有统计学意义（均P<0.05）；研究组中血小板减少、血红蛋白减少、呕吐、肝功能损害、肾功能损耗、皮疹等发生率分别为40.7%、22.2%、59.2%、11.1%、7.4%、14.8%，高于对照组中各不良反应发生率分别为33.3%、18.5%、55.5%、 14.8%、11.1%、7.4%，但两组间差异无统计学意义（P>0.05）。结论：培美曲塞+顺铂方案诱导化疗联合同期放化疗对局部晚期非小细胞肺癌治疗效果明显，且不良反应少，可作为临床上晚期非小细胞肺癌化疗一线药物。

英文摘要:

Objective:To study of short-term efficacy and safety of pemetrexed combined with cisplatin induction concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer.Methods:54 cases of patients with non-squamous non-small cell who treated in Oncology of our hospital from July 2009 to July 2011, were randomly divided into study group and control group, 27 cases in each group, which study group received pemetrexed and cisplatin induction combined with concurrent chernoradiotherapy, and control group were given pemetrexed and cisplatin. all patients were treating two years and following one year, compared the term effect and adverse reactions of two groups.Results:Short-term efficienecy and control rate of study group were 55.56% and 77.78%, higher than 50.33%, 59.26%of control group, the difference between the two groups having statistically significance (P<0.05).T he median survival time and survival rate of one year were 12.77 months, 48.15%, higher than 11.28 months and 40.74%, but, the difference between the two groups was no statistically significance(P>0.05), and the survival rate of two year were 43.46%, higher than 25.38%of control group, the difference between the two groups having statistically significance (P<0.05). The incidence of leukopenia deceasing and alopecia of study group were 37.0%, 25.9%, significanly lower than the 81.5%, 55.5%in control group, the diffierence of two groups having statistically significance (P<0.05). The incidence of thtombocytopenia, hemoglobin decreased, vomit, liver damage, kidney damage and rash were 40.7%, 22.2%, 59.2%, 11.1%, 7.4%, 14.8%, lower than 33.3%, 18.5%, 55.5%, 14.8%, 11.1%, 7.4%of control group, but no significant difference between the two groups(P>0.05).Conclusion:Pemetrexed combined with cisplatin induction concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer had obvious effect ,and less adverse reaction, and which can be as first-line drugs of treating non-small-cell lung cancer.

查看全文查看/发表评论下载PDF阅读器

关闭